Endocrine signaling research
CJC-1295 with DAC
Lyophilisiertes Peptid zur Forschung zu endokrinen Signalen zur Systemüberprüfung
CJC-1295 with DAC is a longer-acting GHRH analog studied for extended GH-axis signaling and albumin-binding pharmacology.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesNur für Laborforschungszwecke. Nicht für den menschlichen oder veterinärmedizinischen Gebrauch bestimmt. Nicht zur Diagnose, Behandlung, Heilung, Linderung oder Vorbeugung von Krankheiten bestimmt.
Verschlossen, kalt, trocken und vor Hitzeschwankungen geschützt aufbewahren. Bestätigen Sie die produktspezifische Lagerung bei der Ankunft.
Verpackt für Transportstabilität mit Bestellunterstützung für Routen bei warmem Wetter.
Batch-linked certificate support is available through the documentation desk.
Forschungskontext
CJC-1295 with DAC Forschungsprofil
CJC-1295 with DAC is a longer-acting GHRH analog designed to extend exposure through drug-affinity-complex chemistry and albumin binding. Research examines pharmacokinetics, prolonged GH and IGF-1 marker changes, pituitary signaling, and how sustained activity differs from shorter GHRH analogs. It is distinct from CJC-1295 No DAC, which is used for shorter pulse-pattern comparisons, and from ipamorelin or GHRP compounds, which signal through the ghrelin receptor. This version is most relevant when half-life extension is central to the study design. Published pharmacology for named investigational material does not independently verify the sequence, purity, or performance of a catalog batch.
Vorgeschlagener Mechanismus
A GHRH analog containing a drug-affinity-complex group designed to form a covalent bond with serum albumin. Albumin binding reduces clearance and prolongs GHRH-receptor stimulation, increasing GH secretion and downstream IGF-1.
In Studien berichtete Effekte
- Healthy-adult studies reported dose-dependent increases in GH lasting several days and increases in IGF-1 lasting approximately one to two weeks after studied exposures.
- Repeated exposure in pharmacology studies produced sustained elevation of GH and IGF-1 without eliminating pulsatile secretion.
- Reported observations included injection-site reactions and endocrine changes expected from prolonged GH-axis stimulation.
Häufige Forschungsendpunkte
Albumin binding, half-life, GHRH receptor activity, GH pulse pattern, integrated GH exposure, IGF-1, glucose, insulin, binding proteins, pharmacokinetics, and adverse events.
Evidenz und Grenzen
Controlled human pharmacology exists for the original investigational CJC-1295 with DAC. Product sequence and DAC chemistry must match before those data are considered relevant.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.
Keep comparing
Compare other catalog records.
Explore related research materials. These are not a combined-use recommendation.
-
GH axis Forschungspeptid
CJC-1295 No DAC
CJC-1295 No DAC is a short-acting GHRH analog studied as a pituitary GH-axis signaling reference.
- Form
- Lyophilisiertes Pulver
- Menge
- 5 mg
Preisspanne: 34.99 $ bis 259.99 $ Ausführung wählen Dieses Produkt weist mehrere Varianten auf. Die Optionen können auf der Produktseite gewählt werden